Literature DB >> 6753888

Absorption and antidysrhythmic activity of oral disopyramide phosphate after acute myocardial infarction.

C R Kumana, V S Rambihar, K Willis, R N Gupta, P H Tanser, J A Cairns, R A Wildeman, M Johnston, A L Johnson, M Gent.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6753888      PMCID： PMC1427608          DOI： 10.1111/j.1365-2125.1982.tb02024.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  19 in total

1.  Correlation of disopyramide pharmacokinetics with efficacy in ventricular tachyarrhythmia.

Authors:  R E Rangno; W Warnica; R I Ogilvie; J Kreeft; E Bridger
Journal:  J Int Med Res       Date:  1976       Impact factor: 1.671

2.  Acute termination of cardiac arrhythmias with intravenous disopyramide.

Authors:  H F Mizgala; P R Huvelle
Journal:  J Int Med Res       Date:  1976       Impact factor: 1.671

3.  Disopyramide in renal impairment.

Authors:  B Whiting; H L Elliott
Journal:  Lancet       Date:  1977 Dec 24-31       Impact factor: 79.321

4.  Disopyramide in myocardial infarction.

Authors: 
Journal:  Lancet       Date:  1977-12-03       Impact factor: 79.321

5.  Congestive heart failure caused by oral disopyramide.

Authors:  P J Podrid; A Schoeneberger; B Lown
Journal:  N Engl J Med       Date:  1980-03-13       Impact factor: 91.245

6.  Anti-arrhythmic and haemodynamic effects of intravenous and oral disopyramide in patients with ventricular arrhythmia.

Authors:  J Hulting; G Rosenhamer
Journal:  J Int Med Res       Date:  1976       Impact factor: 1.671

7.  Pharmacokinetics of digoxin in patients with acute myocardial infarction.

Authors:  U R Korhonen; A J Jounela; A J Pakarinen; P J Pentikäinen; J T Takkunen
Journal:  Am J Cardiol       Date:  1979-11       Impact factor: 2.778

8.  Disopyramide kinetics in patients with acute myocardial infarction.

Authors:  K F Ilett; B W Madsen; J D Woods
Journal:  Clin Pharmacol Ther       Date:  1979-07       Impact factor: 6.875

9.  Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial.

Authors:  J A Sbarbaro; D A Rawling; H A Fozzard
Journal:  Am J Cardiol       Date:  1979-09       Impact factor: 2.778

10.  Oral disopyramide for the prevention of arrhythmias in patients with acute myocardial infarction admitted to open wards.

Authors:  N Zainal; D J Carmichael; J W Griffiths; E M Besterman; P H Kidner; A D Gillham; G D Summers
Journal:  Lancet       Date:  1977-10-29       Impact factor: 79.321
View more
  7 in total

Review 1.  Effects of cardiovascular disease on pharmacokinetics.

Authors:  V Rodighiero
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

2.  Anticholinergic activity in the serum of patients receiving maintenance disopyramide therapy.

Authors:  E Iisalo; L Aaltonen
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

3.  Prophylaxis against ventricular arrhythmias in suspected acute myocardial infarction: a comparison of tocainide and disopyramide.

Authors:  R A Allen-Narker; C J Roberts; A J Marshall; S C Jordan; D W Barritt; R M Goodfellow
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics of disopyramide.

Authors:  L A Siddoway; R L Woosley
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 5.  Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.

Authors:  R N Brogden; P A Todd
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

6.  Sustained release disopyramide compared to plain capsules after change-over from intravenous infusion.

Authors:  E Lien; O M Bakke
Journal:  Br J Clin Pharmacol       Date:  1983-07       Impact factor: 4.335

7.  Disopyramide pharmacokinetics in patients with acute myocardial infarction.

Authors:  P J Pentikäinen; H Huikuri; A J Jounela; G Wilen
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.